Findings
Background and motivation
Materials and methods
Characteristic
|
N
|
%
|
---|---|---|
Male | 17 | 57% |
Female | 13 | 43% |
Diagnosis | ||
Non-small cell lung cancer | 18 | 60% |
Small cell lung cancer | 4 | 13% |
Esophageal cancer | 5 | 17% |
Gastroesophageal junction cancer | 2 | 7% |
Thymic carcinoma | 1 | 3% |
Stage | ||
I | 1 | 3% |
II | 6 | 20% |
III | 13 | 43% |
IV | 5 | 17% |
Limited small cell lung cancer | 4 | 13% |
Recurrent | 1 | 3% |
Prior resection | ||
Yes | 7 | 23% |
No | 23 | 77% |
Induction chemotherapy | ||
Yes | 7 | 23% |
No | 23 | 77% |
Concurrent chemotherapy | ||
Yes | 24 | 80% |
No | 6 | 20% |
Cardiac
|
Pulmonary
| |||
---|---|---|---|---|
Parameter
|
Median (range)
|
Mean ± SEM
|
Median (range)
|
Mean ± SEM
|
Mean organ dose (Gy) | 12.7 (0.6-41.0) | 13.4 ± 1.9 | 14.0 (3.3-34.3) | 14.1 ± 1.1 |
Maximum organ dose (Gy) | 50.3 (1.6-73.4) | 47.0 ± 3.7 | 57.9 (42.7-80.5) | 61.3 ± 1.9 |
V5Gy (%) | 63.4 (0–100) | 55.7 ± 6.8 | 61.3 (10.0-92.3) | 58.1 ± 4.2 |
V10Gy (%) | 44.8 (0–100) | 42.1 ± 5.9 | 43.5 (7.9-87.1) | 42.7 ± 3.4 |
V15Gy (%) | 31.5 (0–100) | 33.2 ± 5.3 | 34.5 (7.1-82.2) | 34.0 ± 2.8 |
V20Gy (%) | 22.1 (0–100) | 27.3 ± 4.9 | 26.6 (5.1-78.0) | 27.2 ± 2.6 |
V30Gy (%) | 11.9 (0–87.3) | 16.9 ± 3.7 | 14.3 (2.4-65.3) | 16.9 ± 2.2 |
V40Gy (%) | 4.3 (0–65.0) | 9.4 ± 2.7 | 8.3 (0.3-42.2) | 10.4 ± 1.7 |
V50Gy (%) | 0 (0–15) | 2.0 ± 0.6 | 3.0 (0–20.0) | 4.5 ± 0.9 |
V60Gy (%) | 0 (0–3.2) | 0.3 ± 0.1 | 0 (0–8.1) | 1.8 ± 0.5 |
V70Gy (%) | 0 (0–0.2) | 0 | 0 (0–2.6) | 0.2 ± 0.1 |